Close Menu

NEW YORK — French diagnostics firm Novacyt said on Thursday that it has received CE marking for its Winterplex PCR-based respiratory panel, which can differentiate SARS-CoV-2 from common winter infections.

Winterplex includes two gene targets specific to SARS-CoV-2, as well as gene targets for influenza A and B and respiratory syncytial virus. According to Novacyt, Winterplex has demonstrated 100 percent specificity and 96 percent to 100 percent sensitivity across the panel in clinical testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.